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INTRODUCTION
Markers are sought to detect conditions or predict future onset of conditions. Examples
include childhood screening tests, tests for genetic abnormalities, and markers for cardiovascular
disease such as serum lipids and inflammatory indicators. Biomarkers for cancer detection
include prostate specific antigen and CA-125. Some of these same markers are used as markers
of treatment response and of disease progression. The emergence of new technologies such as
gene and protein expression arrays promise the development of more sophisticated markers in
the near future.1,2
The issue here is how to evaluate the performance of a marker. The importance of
rigorously evaluating a marker’s performance before it is adopted in routine medical practice is
of particular concern to regulatory agencies and has recently been highlighted in the popular
press.3 The ultimate validation of a marker requires large population studies and consideration of
disease-specific costs and benefits associated with incorrect and correct classification by the
marker.4 Preliminary to such studies are smaller studies that simply assess the marker’s ability to
discriminate subjects with the condition from those without. The statistical evaluation of a
marker’s discriminatory capacity is the specific topic we discuss in this paper.
How should one measure the discriminatory capacity of a marker? An appropriate
measure should not depend on the measurement units of the marker. If it does, it cannot be used
to compare markers measured in different units. For example, the odds ratio (or relative risk) per
unit increase in the marker, although commonly used, is not a self-contained summary statistic of
discrimination and cannot be compared across different markers.6
We propose an approach that first involves standardizing the marker values relative to a
normative population (those without the condition). This standardization puts different markers
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on a common scale, thereby facilitating comparisons amongst markers. In addition we show that
the distribution of the standardized marker among subjects with the condition is closely related to
the receiver operating characteristic (ROC) curve, a statistical tool that has long been used for
evaluating diagnostic tests. 7—9 The ROC curve is appropriate for evaluating the discriminatory
capacity of any marker.10 Its interpretation as relating to the distribution of standardized marker
values is appealing. In particular it may be of interest to those researchers already comfortable
with statistical concepts of standardization and frequency distributions, but who are not familiar
with ROC analysis.
METHODS
Datasets
To illustrate concepts we apply statistical techniques to two simple datasets. The data are
online at http://www.fhcrc.org/labs/pepe/book/. In the first, two serum biomarkers for pancreatic
cancer, CA-125 and CA19-9, were measured for 90 patients with pancreatic cancer and 51
without11 (Figure 1). Questions of interest are: (i) how to quantify the capacities of the two
markers to distinguish between the patients with and without cancer; and (ii) to compare the two
markers.
The second dataset pertains to a marker of hearing impairment at the 1416 Hz freqeuncy
for 57 hearing impaired ears and 147 unimpaired ears. The marker is the signal-to-noise ratio
(SNR) from the distortion product otoacoustic emissions (DPOAE) test. The test was performed
using 9 different sound stimulus intensity levels, 3 of which are included in this dataset. Thus for
each ear we have an SNR value for each of the intensity levels (Figure 2). Details of the original
study and data selection can be found in Stover et al12 and in Pepe,13 respectively.
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Both of these studies employed case-control designs. Cross-sectional cohort studies can
be analysed in the same way.
Approach
To explain the general approach we adopt the convention that higher values of the marker
are more indicative of the presence of the condition. (We can always redefine the marker if
necessary to ensure this, using negation for example. See the audiology data in Figure 2.) The
basic idea is to use the distribution of marker values in the unaffected population, without the
condition, as a reference distribution for standardizing marker values in the affected population,
i.e., those with the condition. The standardization for an affected subject with marker value Y is
simply to calculate the frequency of unaffected subjects with marker values greater than Y. Thus
if marker values for 20% of unaffected subjects exceed Y, the standardized marker value is 0.20.
We call the standardized value its placement value.14—16
The concept of calculating a placement value is closely related to that of calculating a
percentile value relative to a healthy reference population as is the common practice for reporting
anthropometric measurements in children.17 Here, rather than reporting the percentile, the
proportion of the reference population less than Y, we report the proportion greater than Y.
Although the concepts are equivalent, we will see that calculation of placement values rather
than percentiles facilitates connections with ROC methodology.
Placement values are proportions taking values between 0 and 1. Since higher marker
values are more indicative of the condition, having the condition is associated with having
smaller placement values. The smallness of the placement value indicates how extreme a
subject’s marker value is relative to the reference population. Moreover, a marker for which most
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affected subjects have very small placement values is a good marker because it identifies most
affected subjects as being extreme relative to the reference population.
A key attribute of placement values is that they do not have measurement units associated
with them. Different markers are converted to a common scale by the placement value
standardization. This facilitates comparisons amongst them. Thus if a diseased subject has a
placement value of .50 for marker 1 and placement value .01 for marker 2, then marker 2 is the
better disease indicator for him. He is identified as extreme in regards to marker 2 while he
appears to be well within the reference (non-diseased) population in regards to marker 1. To
determine which of two markers is better at discriminating the population of affected subjects
from the unaffected population, one must consider the population distributions of placement
values in affected subjects for each of the markers. The marker with a higher frequency of small
placement values is preferred.
ROC Curve
The ROC curve is a statistical device for illustrating the classification accuracy
achievable with a diagnostic test, or marker.9,10,16 For each possible threshold value, c, one can
define a positive classification rule based on the marker, Y ≥ c indicating that the condition is
present. The associated true positive rate (TPR(c)) and false positive rate (FPR(c)) are
TPR (c) = proportion of affected subjects with Y ≥ c

and
FPR (c) = proportion of unaffected subjects with Y ≥ c ,
respectively. The ROC curve plots TPR (c) , the test sensitivity, versus FPR (c) , 1-specificity, for
all values of c. It shows the range of (FPR, TPR) achievable. Since good classification accuracy
pertains to low FPRs and high TPRs, a good marker has an ROC curve with points in the upper
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left corner of the (0,1) × (0,1) square. The area under the ROC curve (AUC) is the most popular
ROC summary statistic. An AUC of 1.0 corresponds to a perfect marker.
RESULTS
Pancreatic Cancer Biomarkers

Using the 51 subjects without pancreatic cancer as the reference group we standardized
each of the markers for the 90 subjects with pancreatic cancer by calculating placement values.
The frequency distributions are displayed in Figure 3a. The CA-19-9 placement values are
smaller than the CA-125 values indicating that pancreatic cancer patients are more extreme
relative to the non-cancer reference in regards to CA19-9 than in regards to CA-125
The average (sd) of the placement values is .14 (.26) for CA 19-9 and .29 (.25) for CA125. A simple paired t-test could be applied to compare the averages. However it is not quite
appropriate because a finite sample of only 51 non-cancer patients was used to standardize the
markers. A different sample of non-cancer patients would have produced a somewhat different
standardization. The sampling variability in the reference group used to calculate the placement
values for the 90 diseased subjects must be accounted for in calculating a p-value that compares
mean CA-19-9 and CA-125 placement values. The bootstrapping technique18 described in the
electronic appendix does this and yields p < .01.
The scatterplot (Figure 3(b)) shows that although CA19-9 is the better marker overall,
there are a substantial number of cancer patients for whom CA-125 is better in the sense that
they are normal in regards to CA19-9 but abnormal in regards to CA-125. For example, 5
patients with CA-19-9 placement values exceeding 20% had CA-125 values less than 10%.
Audiology Testing
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Distributions of standardized –SNR values (negative SNR) are shown in Figure 4 for
hearing impaired subjects. It appears that the test is more discriminatory when the sound
stimulus is at a lower intensity since the placement values are smaller at the 55dB intensity level
versus at the 60 and 65 dB levels. The average (sd) values are .029 (.057), .053 (.106), and .071
(.127), respectively. The p-value for comparing the averages at 55 and 65dB is < .01 using the
bootstrap technique. Interestingly the 55 dB stimulus appears to work better than the 65dB
stimulus for most individuals as can be seen from the scatterplot in Figure 4 (b). That is, the test
results for most hearing impaired subjects appeared more abnormal with the lower intensity
stimulus, as evidenced by smaller placement values.
Relationship with ROC analysis

Figures 3(c) and 4(c) show the cumulative distributions (cdf) of standardized markers for
cancer patients and for hearing impaired subjects respectively. The cdf corresponding to p on the
x-axis is the proportion of values that are ≤ p. Interestingly these cumulative distribution curves
are identical to ROC curves for the markers. The general argument is as follows: Let c be the
threshold value that corresponds to the false-positive rate p, FPR (c) = p . Consider the point
cdf(p) on the cumulative distribution curve. Observe that a subject’s placement value is ≤p if and
only if his marker value Y ≥c. Therefore the proportion of affected subjects with placement
values ≤p, namely cdf(p), is equal to the proportion with marker values ≥c, i.e., TPR (c) . So,
each point (p, cdf(p)) on the cumulative distribution curve is a point (FPR(c), TPR(c)) on the
ROC curve and vice versa. A mathematical argument is given in Pepe and Cai.15
There are two interpretations then for the curves shown in Figures 3(c) and 4(c).
Interpreted as cumulative distribution functions, we see the proportion of affected subjects with
standardized marker values as or more extreme than p. Interpreted as ROC curves we see the
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trade-offs between sensitivity and specificity that are possible when we apply thresholding
classification rules to the marker in the population. Both interpretations are meaningful and
useful. The accuracy of CA19-9 for classifying subjects with or without pancreatic cancer is
clearly superior to CA-125. For example, the thresholding rule with specificity of 80%
(FPR=.20) yields a sensitivity of 78% for CA19-9 but only 49% for CA-125. Said another way,
78% of cancer patients have standardized CA-19-9 below 0.2 while only 49% have standardized
CA-125 below 0.2. Similarly we see from Figure 4 (c) that classification accuracy is better when
the lower sound intensity is employed.
ROC Summary Statistics

The areas under the ROC curves in Figure 3(c) are .86 for CA 19-9 and .71 for CA-125.
Those in Figure 4(c) yield AUCs of .97 at 55 dB, .95 at 60 dB, and .93 at 65 dB. Observe that
these are exactly the same as 1 minus the mean placement values calculated earlier. The result
holds in general that averaging standardizing markers for affected subjects yields 1–AUC.
average (placement value)=1–AUC.
It is intuitive for the perfect marker since all placement values for affected subjects are equal to 0
and AUC = 1 for the perfect marker. Mathematical arguments for the general result are
available.14,15
The implication of this result is that statistical comparisons between markers using areas
under ROC curves are the same as statistical comparisons between markers using placement
value averages for diseased subjects. Therefore the p-values cited earlier that pertain to average
placement values are also valid for comparing the AUCs in Figures 3(c) and 4(c).
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DISCUSSION

The main contribution of this paper is to suggest a standardization procedure to facilitate
the evaluation of markers. Use of a reference distribution is a familiar concept. In laboratory
medicine for example values outside of a normal healthy reference range often flag patients as
having a medical condition. Standardization with respect to an age and gender matched reference
population is used for anthropometric measurements. Standardization not only provides better
clinical interpretations but makes possible valid comparisons of different populations. Our
standardization can be used to compare a marker's discriminatory capacity across different
populations. One could compare placement values in diseased men and diseased women, for
example, to determine if the marker performs better in men or women. An additional compelling
attribute of the standardization we propose is that it makes possible valid comparisons of
different markers across the same population, as demonstrated with our two datasets.
We also noted the close connection between analysing standardized markers of affected
subjects and ROC analysis. With our approach one can analyze standardized markers in familiar
ways, as we did for pancreatic cancer and hearing impairment markers, without explicitly
considering operating characteristics of thresholding decision rules. Nevertheless we have shown
that such considerations are implicitly at play and the approach is fundamentally the same as
ROC analysis.
Our approach offers avenues for addressing questions that should be, but are typically not
asked about marker performance. In particular, regression analysis applied to placement values
can be used to determine if covariates affect the capacity of a marker to distinguish cases from
controls.15,19 Covariates may relate to characteristics of subjects tested or to the test itself. 16 To
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illustrate with the audiology data, the following linear regression model was fit to the placement
values for hearing impaired subjects:
Z = Z (placement value) = α 0 + α 1 Intensity + ε
with Z, the normal deviate corresponding to the placement value, and covariate, Intensity, being
the sound stimulus intensity. The estimate α 1 = 0.023 (95% confidence interval =(-.019, .076);
se=.024) indicates a trend for higher intensity levels being associated with larger placement
values among hearing impaired subjects, i.e., reduced marker performance. Figure 4c shows the
corresponding cumulative distributions of placement values. The more frequent occurrence of
small placement values at the lower intensity levels is obvious from these curves. The better
performance at lower intensity is also evident with the ROC curve interpretation. More complex
models that include multiple independent variables simultaneously can easily be fit too. As noted
earlier, bootstrapping is applied to arrive at appropriate standard errors and p-values.
Alternatively, recent work15,19 provides theory for making statistical inference about regression
models using placement values.
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Appendix: Testing for a difference in the mean Placement Value between two disease markers:

Bootstrap estimation of the achieved significance level.

With paired observations on the two markers, A and B, the test statistic is the average
placement value difference between markers,

θˆ =
where n = number of cases, and

W

i

(

)

1
B
A
−W i ,
∑
W
i
n i

is the placement value of the marker for case i and the

superscript indicates the marker. The null hypothesis to be tested is H 0 : θ = 0 . The sampling
variability of placement values calculated for disease cases depends not only on marker
variability among the cases but also among the controls used to estimate the reference
distribution.
In order to approximate the null distribution of θˆ and estimate the achieved significance
level, we sampled from the empirical distribution of θˆ and centered the distribution at zero, the
desired null mean. Specifically, samples of paired marker observations, equal in size to the
original case and control samples, were drawn separately, with replacement, from the observed
case and control samples. The test statistic, θˆk , was calculated for each set of case and control
“bootstrap” samples, k = 1, ... 1000, and translated to conform to the null distribution by
subtracting the original θˆobs from the bootstrap sample, θˆk∗ = θˆk − θˆobs . The achieved
significance level of the test was then calculated as the proportion of the bootstrap θˆk∗ ’s more
extreme than the observed θˆobs , i.e. θˆk∗ ≥ θˆobs .
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FIGURE LEGENDS
Figure 1. Distributions of pancreatic cancer biomarkers in 51 subjects with pancreatic
cancer and 90 subjects without cancer.
Figure 2. Distributions of –SNR values from the DPOAE test in 57 ears with hearing
impairment and in 147 ears without impairment at the 1416 HZ frequency. The test was
applied using input stimulus of intensities 55 dB, 60 dB and 65 dB. Shown are –SNR values
(rather than SNR values) to agree with the convention of higher marker values being more
indicative of hearing impairment.
Figure 3. Distributions of standardized biomarkers (placement values) in 90 subjects
with pancreatic cancer. Shown are (a) frequency distributions (b) scatter plots and (c)
cumulative distributions .
Figure 4. Distributions of placement value standardized –SNR in 57 hearing impaired
ears at 3 stimulus intensity levels (55 dB, 60 dB, and 65 dB). Shown are (a) frequency
distributions, (b) scatter plots and (c) cumulative distributions .
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